Press Release: Exai : Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Exais liquid biopsy platform detects early-stage disease with high accuracy and uniquely distinguishes invasive breast cancer from low grade ductal carcinoma in situ The company is also...
Read full article »
Exai Bio is a California-based biotechnology company that develops oncRNA and AI-driven liquid biopsy technology for the treatment of cancer diagnosis.
Read more